



Contact:

David Waldman or Justyna Gudaszewska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: +48 693 354 580

**Results of New Clinical Study Show
Epidural Space Correctly Identified in 100% of Labor & Delivery Patients
Using Milestone Medical's CompuFlo™ Epidural Instrument**

Results Featured in Abstract Presentation at the 45th Chilean Congress of Anesthesiology

LIVINGSTON, NJ, November 15, 2017 -- Milestone Medical Inc. (WAR:MMD) today announced that Dr. Camila Gonzalez of Department of Anesthesiology Davila Clinic, Los Andes University, Santiago, Chile, presented an abstract at the 45th Chilean Congress of Anesthesiology on November 11, 2017, entitled: UTILIZATION OF DYNAMIC PRESSURE SENSING IN EPIDURAL PUNCTURE FOR LABOR.

The abstract summarizes the results of a new clinical study evaluating the use of Milestone's CompuFlo™ Epidural Instrument in 50 labor and delivery patients. The epidural space was correctly identified in 100% of the patients. In addition, the epidural space was recognized on the first attempt in all of the patients. There were no cases of accidental dural puncture, a common risk factor for traditional epidural procedures using the loss of resistance technique.

Dr. Mark Hochman, D.D.S, Director of Clinical Affairs for Milestone Scientific, the licensor and the majority shareholder of Milestone Medical Inc. commented, "The results of this study reinforce the advantages of our technology. Not only was the epidural space correctly identified in 100% of patients, but it was recognized on the first attempt. This represents a significant benefit for the payors, physicians, and most importantly, the patients."

"We are pleased to see the CompuFlo™ Epidural Instrument featured in an independent, investigator-led clinical study. The abstract presentation at the 45th Chilean Congress of Anesthesiology represents the first formal presentation of our CompuFlo™ Epidural Instrument in South America, and we are excited to see the technology rapidly gaining recognition around the world," continued to Dr. Hochman

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Justyna Gudaszezwska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: +48 693 354 580

Media:

Shep Doniger
Black Dog Communications Group
Email: sdoniger@bdcqinc.com
Tel: 561-637-5750